OPIOIDSOPIOIDS

DEFINITIONSDEFINITIONSOpium : a mixture of alkaloids from the poppy

plant - papaver somniferum

Opioid : any naturally occurring, semi-synthetic or synthetic compounds that bind specifically to opioid receptors and share the

properties of one or more of the naturally occurring endogenous opioids

Opiate : any naturally occurring opioid derived from opium

Narcotic : Greek word meaning to numb or deaden. denote an opioid but also widely used to describe drugs of addiction and hence includes non opioid compounds

MECHANISM OF ACTIONActivate opioid receptors.Opioid receptors are distributed throughout the CNS with high concentrations in the nuclei of tractus solitarus, peri-aqueductal, cerebral cortex, thalamus & substantia gelatinosa of the spinal cord.

Opioid receptors are coupled with inhibitory G-proteins & their activation has a number of actions:

- closing of voltage sensitive calcium channels, - stimulation of potassium efflux leading to hyperpolarization & reduced cyclic adenosine monophosphate (cAMP) production.

Overall, the effect is a reduction in neuronal cell excitability - reduced transmission of nociceptive impulses.

MECHANISM OF ACTION

AgonistPure opioid agonists bind to opioid receptors avidly & demonstrate high intrinsic activity at the cellular level.

Eg : Morphine

Partial Agonist

Partial opioid agonists (buprenorphine) bind to opioid receptors but produce a sub-maximal effect compared to pure agonists.

Antagonisthave receptor affinity but no

intrinsic activity.Eg : Naloxone

MCQMCQDrugs which could potentially

prevent an abstinence withdrawal syndrome during hospitalization include:A. morphineB. nalbuphineC. methadoneD. butorphanolE . Hydromorphone

OPIOID RECEPTORSSince their identification, opioid receptors

have had a variety of names.Current nomenclature approved by

International Union of Pharmacology :◦ MOP (mu opioid peptide receptor )◦ KOP (kappa opioid peptide receptor)◦ DOP (delta opioid peptide receptor)◦ NOP (nociceptin orphanin FQ peptide

receptor)The sigma receptor is no longer classified

as an opioid receptor.A number of different subtypes of each

receptor exist; 2 MOPs, 3 KOPs & 2 DOPs.

Endogenous opioidsProduced in the body and widely

distributed throughout the CNS.They have numerous actions

including modulation of pain & control of the CVS system, particularly in shock.

Endogenous opioids currently have no clinical role.

RECEPTOR TYPE

Opioid MOP KOP DOP NOP

Endogenous

Beta endrophin +++ +++ +++ -

Leu-enkaphin + - +++ -

Dynorphin A & B ++ +++ + +

N/OFQ - - - +++

Clinical drugs

Agonists

Morphine +++ + + -

Pethidine +++ + + -

Diamorphine +++ + + -

Fentanyl +++ + - -

Partial agonists

Buprenorphine ++ + - -

Pentazocine - ++ - -

Antagonists

Naloxone +++ ++ ++ -

Naltrexone +++ ++ ++ -

Opioids with their selectivity for different opioid receptors

+ = low affinity; ++ = moderate affinity; +++ = high affinity; - = no affinity

CLASSIFICATION OF OPIOIDS

Several classification :◦Traditional : based upon

analgesic potency◦Origin of drug : naturally occurring

or manufactured

◦Function : their action at the opioid receptor

Traditional Origin FunctionStrong Naturally occurring Pure agonists

Morphine Morphine Morphine

Pethidine Codeine Fentanyl

Fentanyl Papavarine Alfentanil

Alfentanil Thebaine Remifentanil

Remifentanil Semisynthetic Sufentanil

Sufentanil Diamorphine Partial agonist

Intermediate Dihydrocodeine Buprenorphine

Buprenorphine Buprenorphine Agonists-antagonists

Pentazocine Synthetic Pentazocine

Butorphanol Phenylpyperidines : Nalbuphine

Nalbuphine Pethidine,fentanyl, alfentanil Nalorphine

Weak Sufentanil Pure Antagonists

Codeine Diphenylpropylamines : Naloxone

Methadone, dextropropoxyphene

Naltrexone

Morphinans :

Butorphanol, leverphanol

Benzomorphans

Pentazocine

Classification of opioidsClassification of opioids

MCQThe following statements regarding the

pharmacodynamics of opioids are true:a) naloxone is more effective at mu receptors than at other opioid receptorsb) unchanged diamorphine has no affinity for opioid receptorsc) pethidine penetrates the blood-brain barrier quicker than morphined) pethidine may be used safely in patients receiving monoamine oxidase inhibitorse) the duration of action of remifentanil is prolonged by concomitant administration  of anticholinesterase drugs

PHARMACODYNAMIC OF

OPIOID AGONISTS

CNS1) Analgesia

most effective in relieving dull, continuous & poorly localised pain arising from deeper structures, eg. gut.

Less effective against superficial & sharp pain.

2) Sedationdrowsiness, feeling of heaviness & difficulty in

concentrating are common.sleep may occur with relief of pain, although

they are not true hypnotics.

3) Euphoria & dysphoria morphine & other opioids cause sense of

contentment & well-being.if there is no pain, morphine may cause

restlessness & agitation.

CNS cont....

4) Hallucination these are common with KOP agonists, but

morphine & other MOP agonists may also cause hallucinations.

5) Tolerance & Dependence tolerance is the decrease in effect seen despite

maintaining a given concentration of a drug dependence exists when the sudden withdrawn

of an opioid, after repeated use over a prolonged period, results in various physical & psychological signs.

This include restlessness, irritability, increased salivation, lacrimation & sweating, muscle cramps, vomiting & diarrhoea.

CVS

mild bradycardia is common as a result of decreased sympathetic drive & a direct effect on the SA node.

RESPIRATORY SYSTEM

Respiratory depression is mediated via MOP receptors at the respiratory centres in the brainstem.

Respiratory rate falls more than tidal volume & the sensitivity of the brain stem to carbon dioxide is reduced.

Response to hypoxia is less affected but if hypoxic stimulus is removed by supplemental oxygen then respiratory depression may be augmented.

Concurrent use of of other CNS depressant for example BDZ or halogenated anaesthetic, may cause marked respiratory depression.

Opioids suppress cough.

GIT

stimulation of the CTZ causes nausea and vomiting.

smooth muscle tone is increased but motility is decreased resulting in delayed absorption, increased pressure in the biliary system and constipation.

ENDOCRINE

the release of ACTH, prolactin, gonadotrophic hormone is inhibited.

secretion of ADH is increased.

OCULAR

MOP & KOP receptors in Edinger-Westphal nucleus of occulomotor nerve are stimulated resulting in constriction of the pupils (meiosis).

Histamine release & itchingsome opioids cause histamine release from

mast cells resulting in urticaria, itching, bronchospasm & hypotension.

itching occurs most often after intrathecal opioids & is more pronounced on the face, nose and torso.

mechanism is centrally mediated & may be reversed by naloxone.

Muscle rigiditylarge doses of opioids may occasionally

produce generalised muscle rigidity especially of thoracic wall & interfere with ventilation.

Immunityimmune system is depressed after long

term opioid abuse.

Effects on Pregnancy and Neonatesall opioids cross the placenta & if given

during labour, can cause neonatal respiratory depression.

chronic use by the mother may cause physical dependence in utero & lead to a withdrawal reaction in the neonate at birth that can be life threatening.

there are no known tetratogenic effects.

MCQRegarding the pharmacokinetics of

opioid analgesics:a) bioavailabilty of most of the opioids given by the oral route is about 75-85%b) highly water soluble opioids have a rapid onset of actionc) the duration of action of opioids is related to their terminal half-livesd) they have flow-dependent hepatic clearancee) morphine has a terminal half-life similar to fentanyl

Pharmacokinetics of commonly used Pharmacokinetics of commonly used opioidsopioids

Morphine Penthidine

Fentanyl

Alfentanil

Remifentanil

pKa 8.0 8.5 8.4 6.5 7.1

Unionised at pH 7.4 (%)

23 5 9 90 68

Plasma protein bound (%)

30 40 84 90 70

Terminal half life (hrs)

3 4 3.5 1.6 0.06

Clearance (ml/min/kg)

15-30 8-18 0.8 – 1.0

4-9 30-40

Volume of distribution (L/Kg)

3-5 3-5 3-5 0.4-1.0 0.2-0.3

Relative lipid solubility

1 28 580 90 50

Opioids are weak bases (pKa 6.5-8.7)In solution they dissociate into ionised &

unionised fractions, the relative proportions depend upon the pH of the solvent & their pKa.

In the acidic environment of stomach, opioids are highly ionised & therefore poorly absorbed.

In the alkaline small intestine, they are predominantly unionised & are readily absorbed.

Undergo extensive first pass metabolism in the intestinal wall & liver, resulting in low oral bioavailability.

High lipid solubility facilitates opioid transport into the biophase or site action and confers a more rapid onset of action.

large volumes of distribution

high lipid solubility, high unionised fractionlow protein binding in the

plasma,

MetabolismRedistribution- small dose of highly lipid solubleMainly in the liver to both active & inactive

compounds that are excreted in urine & bile.Partly in the bile as water soluble glucoronides. In the gut, glucoronides are metabolised by the

by the normal gut flora to the parent opioid compound & reabsorbed (entero-hepaticrecirculation)

Highly lipid soluble opioids, eg. fentanyl, may diffuse from the circulation into the stomach mucosa & lumen, where they are ionised & concentrated because of the low pH & later, gastric emptying & reabsorption from the small intestine may produce secondary peak effect (gastro-enteric recirculation).

Metabolism cont.Extra-hepatic metabolism is

important, kidneys play a vital role in conjugating morphine, whereas blood & tissue esterases are responsible for remifentanil metabolism.

CLINICAL USESAnalgesia: Fentanyl, morphineCough surpression: Codeine,

DextromethorphanAntidiarrheal : Diphenoxylate,

LoperamideAcute pulmonary oedema:

MorphineAnaesthesia : FentanylOpioid Dependence : Methadone

INDIVIDUAL OPIOIDS

The pharmacologic effects of morphine include all EXCEPT

1. behavioral changes2. miosis3. respiratory depression4. diarrhea5. postural hypotension

MORPHINENaturally occurring phenanthrene derivative.The standard drug against which all other

opioids are compared.Route of administration- PO, IV, IM, SC,

rectally, epidurally & intrathecally.Dose is 0.1- 0.2mg/kgFor IM - peak effect is 30-60 minutes & duration

of action is 3-4 hours. IV administration should be titrated to effect

(usually 1-2mg boluses), but the total dose is similar.

The onset of action is slightly more rapid with following IV adminstration, as the main factor responsible for its latency is low lipid solubility & slow penetration of blood brain barrier.

Morphine may be given epidurally at 10% & intrathecally at 1% of the parental dose.

MORPHINE : PHARMACOKINETICSExtensively metabolised by the gut wall & the

liver to morphine 3 glucuronide (M3G)(70%), Morphine-6-glucuronide (M6G)(10%) & to sulphate conjugates.

M6G is 10-20 times more potent than morphine & is normally excreted in urine.

M6G accumulates in renal failure & accounts for increased sensitivity to morphine.

Neonates are more sensitive than adults to morphine due to reduced hepatic conjugating capacity.

In the elderly, owing to reduced volume of distribution, peak plasma level of morphine is higher compared to younger patient

Effects of MorphineMediated through MOP receptors. Potent analgesic with good sedative &

anxiolytic properties. May cause euphoria, dysphoria &

hallucination. Respiratory depression & cough suppression. Minimal effect on cardiovascular system &

may produce bradycardia & hypotension. Nausea & vomiting are common side effects. Histamine release may lead to rash, itching &

bronchospasm (in susceptible patients). Meiosis is common. Tolerance & dependence may develop.

PAPAVERETUMa mixture of hydrochloride salts of opium

alkaloids; morphine hydrochloride, codeine hydrochloride & papaverine hydrochloride.

For moderate to severe pain & as preoperative sedation.

Dose: It can be given SC, IM or IV.5.4 mg of papaveretum contains 10 mg of

morphine.Effectsgreater degree of sedation fewer gastrointestinal side effects. Higher doses - transient but severe

headache, reduces the compound’s addiction potential.

CODEINE

a natural opioid & one of the principal alkaloids of opium.

very low affinity for opioid receptors.

Dose: orally & IM. Adult dose is 30-60 mg by either route and

can be repeated at 6 hours intervalVarying doses (8-30 mg) are commonly

incorporated with NSAIDs in compounds employed in the treatment of mild to moderate pain (eg: Panadeine)

Also use in antitussive & antidiarrhoeal preparations.

•Oral bioavailability is 50%. •About 10% is metabolised to morphine & the rest is metabolised to inactive conjugated compounds. •The metabolism to morphine depends on an isoform of cytochrome P450, which exhibits polymorphism, so that poor metabolizers (approximately 10% people) may experience minimal pain relief.

Effects•It causes little euphoria & has low abuse potential. •Codeine is less sedative and less likely to cause respiratory depression than morphine. •It may cause disorientation & excitement. •Constipation is common side effect. •Dihydrocodeine is a semi-synthetic derivative of codeine with similar pharmacologic effects. •Oxycodone is more effective, but has higher abuse potential.

CODEINE : PHARMACOKINETICSCODEINE : PHARMACOKINETICS

DIAMORPHINE (HEROIN)

A semi-synthetic opioid, the diacetylated analogue of morphine.

It is 1.5-2.0 times more potent than morphine. It is a pro-drug and is converted the active components

of acetylmorphine & morphine by esterases in liver, plasma & central nervous system.

Dose: same routes as morphine in approximately half the

dose. Due to its higher lipid solubility, it is less likely than

morphine to cause delayed respiratory depression when used epidurally or intrathecally.

Can be administered as hydrochloride salt by IM or SC infusion in a smaller volume of solution than equivalent dose of morphine.

important consideration for patients with terminal malignant disease who may require large doses of opioid for pain relief.

Diamorphine: Pharmacokinetics

• 200 times more lipid soluble than morphine, passes more rapidly across the blood-brain barrier into the CNS where it is converted to morphine.

• More potent & rapid onset of action. • Because of the extensive first pass metabolism,

it has low bio-availability. Effects• It shares common opioid effects with morphine. • It is associated with an increased tendency to

cause euphoria & dependency.• May cause less nausea & vomiting than

morphine.

PETHIDINE It is a synthetic phenylpyperidine derivative originally developed as an antimuscarinic agent.

Dose: Pethidine is available as 50 mg tablets & ampoules of different

strength (10 mg/ml and 50 mg/ml). For acute pain, it can be administered orally (50-150 mg), SC

(50-100 mg), IM (50-100 mg) or IV (25-100 mg). The doses can be repeated every 4 hours.

Pharmacokinetics Pethidine is 30 times more lipid soluble than morphine. Oral bio-availability is 50%. Metabolised in the liver by ester hydrolysis to norpethidine &

pethidinic acid that are excreted in urine, therefore accumulate in renal failure.

At higher concentration, norpethidine can produce hallucination & convulsions.

Pethidinic acid is an inactive compound. Often used for labour analgesia. It readily crosses placenta, & a

significant amount reaches to the foetus over several hours.

PETHIDINE cont..EffectsProduces tachycardia, dry mouth & less marked

meiosis. However, significant fall in BP may occur when

pethidine is administered to elderly or hypovolaemic patients.

It may produce less biliary tract spasm than morphine.

Pethidine is absolutely contraindicated in patients on monoamine oxidase inhibitors (MAOI), as serious side effects like hypotension or hypertension, hyperpyrexia, convulsion and coma may occur. The underlying mechanism is not clear but may involve reduced metabolism of pethidine by MAOI & pethidine’s effect on turnover of 5- hydroxytryptamine in the brain.

FENTANYL It is a synthetic phenylpyperidine derivative. It is 100 times more potent than morphine.

Dose: It is available as colourless solution for injection in 2 & 10 ml

ampoules containing 50 microgram per ml. When given in small doses (1-2 microgram/kg), it has rapid

onset & short duration of action (30 minutes). Such doses are used intravenously for pain associated with

minor surgery. In small doses it has little sedative effect. Higher doses are used to obtund sympathetic response to

laryngoscopy & intubation. Fentanyl has been used to augment effects of local

anaesthetics in spinal & epidural analgesia at 10-25 microgram and 25-100 microgram doses respectively.

Fentanyl is also available as transdermal patch for chronic pain conditions & as lollipop to premedicate children.

FENTANYL cont...Pharmacokinetics Fentanyl is 500 times more lipid soluble than morphine,

consequently it is rapidly & extensively distributed in the body (volume of distribution 4 L/kg).

At small doses (1-2 microgram/kg), plasma & CNS concentration fall below an effective level during rapid distribution phase.

However, following prolonged administration or with high doses, its duration of action is significantly prolonged.

In these circumstances, the distribution phase is complete while the plasma concentration is still high.

Recovery from the effect of the drug then depends on its slow elimination from the body (terminal half life 3.5 hours).

Fentanyl is predominantly metabolised in the liver to norfentanyl which is inactive.

The metabolite is excreted in the urine over few days.

Effects:Many properties of fentanyl are similar to morphine.It produces respiratory depression in dose-dependent manner.Large doses (50- 100 microgram/kg) have been used for cardiac surgery to obtund metabolic stress response.At such high doses, sedation is profound & unconsciousness may occur, muscular rigidity of the chest wall may affect ventilation.

FENTANYL cont....

ALFENTANYL Alfentanil is synthetic phenylpyperidine

derivative structurally related to fentanyl; it has 10-20% of its potency.

Dose: Alfentanil is available as colourless solution in

the concentrations of 500 microgram/ml or 5 mg/ml.

It may be administered intravenously as either bolus or continuous infusion.

Bolus doses (10 microgram/kg) are useful for short term analgesia & attenuation of cardiovascular response to intubation.

Continuous infusions (0.5-2.0 microgram/ kg/min) are used in the intensive care unit for sedation in patients on mechanical ventilation.

ALFENTANYL contPharmacokineticsAlthough it has much lower lipid solubility than

fentanyl, more alfentanil is present as unionised form compared to fentanyl (89% compared to 9%); consequently, its onset of action is more rapid.

Lower lipid solubility, less alfentanil is distributed to muscles and fat. Hence, its volume of distribution is relatively small & more of the dose remains in blood from which it can be cleared by the liver.

Even though alfentanil has a lower clearance rate, this is more than offset by its reduced volume of distribution & its half life is relatively short.

Effects: Most effects of alfentanil are similar to fentanyl but

with quicker onset & shorter duration of action.

REMIFENTANYLSynthetic phenylpyperidine derivative of fentanyl

with similar potency but is ultra short-acting. Dose: Available as white crystalline powder in glass vial

containing 1, 2 or 5 mg remifentanil hydrochloride.

A range of infusion rates (0.05- 2.0 microgram/kg/min) are used during maintenance of anaesthesia with controlled ventilation.

PharmacokineticsRapidly broken down by non-specific plasma &

tissue esterases resulting in a short elimination half life (3-10 minutes).

It is context insensitive, in that the half life, clearance & distribution are independent of duration & strength of infusion.

REMIFENTANYL cont...EffectsCertain properties of remifentanil like rapid

onset, rapid offset, organ independent metabolism & lack of accumulation make it suitable for use during various surgical procedures.

However, it should be used cautiously at higher rates of infusion as serious side effects for example bradycardia, hypotension, apnoea & muscle rigidity may occur.

Since there is no residual effect, alternative postoperative analgesic regimen should be established before infusion is terminated.

MCQConcerning pharmacokinetics of

intrathecal opioids. (a) Fentanyl demonstrates significant rostral

spread in the CSF. (b) Morphine has a low volume of

distribution in the spinal cord. (c) ‘Ion trapping’ facilitates fentanyl binding

to receptor sites in the spinal cord. (d) CSF concentration falls rapidly following

injection of fentanyl. (e) Diamorphine is eliminated more rapidly

from the CSF than morphine.

TRAMADOLPhenylpyperidine analogue of

codeine. Weak agonist at all opioid receptors

with 20-fold preference for MOP receptors.

It inhibits neuronal reuptake of norepinephrine.

It potentiates release of serotonin & causes descending inhibition of nociception.

Dose: Oral & parenteral dosage

requirements are similar, 50-100 mg 4 hourly.

TRAMADOL

PharmacokineticsTramadol has high oral bioavailability of

70% which can increase to 100% with repeated doses due to reduction in first pass effect.

It is 20% bound to plasma proteins. It is metabolized in the liver by

demethylation in to a number of metabolites & only one of them (O-desmethyltramadol) has analgesic activity.

Its volume of distribution is 4.0L/kg & its elimination half-life is 4-6 hours.

TRAMADOL cont...TRAMADOL cont...Effects: In equi-analgesic dose to morphine,

tramadol produces less respiratory & cardiovascular depression than morphine.

Constipation is less common. However, tramadol shares most of the

common side effects of other opioids (eg. vomiting, drowsiness and ambulatory dizziness).

Tramadol is contra-indicated in patients on MAOI or with a history of epilepsy.

METHADONEA potent opioid analgesic that is

well absorbed with good oral bioavailability (75%).

However, its main use is as a substitute for opioids for example diamorphine (heroin) in addicts because its slow onset and offset reduces the incidence of withdrawal symptoms.

It is itself addictive.

MCQThe following statements are true

regarding the opioids used in the perioperative period:

a) morphine may raise plasma histamineb) pethidine does not alter the heart ratec) pethidine is more of a myocardial depressant than morphined) sufentanil may not cause truncal rigidity in high dosese) opioid-induced bradycardia is rare in patients undergoing bilateral vagotomy

MCQ13. Regarding partial opioid agonists:a) partial agonists are agonists at m but

antagonists at k receptorsb) buprenorphine has low intrinsic activity at m receptorsc) partial agonists show a plateau or ceiling effect in their dose-response curved) nalbuphine is equipotent with morphinee) buprenorphine is longer acting due to its strong receptor affinity

PARTIAL OPIOID AGONISTThis group of drugs have affinity for opioid

receptors but low intrinsic activity compared to full agonists.

Because of their reduced activity, they are able to antagonise or reduce the responsiveness of a pure agonist like morphine when acting at the same receptor.

In other words, a higher dose of a pure agonist is required in presence of partial agonist, in order to obtain full agonist response.

They can be further divided into two groups:Mixed agonist-antagonist:

They exert agonist effects at one opioid receptor & antagonistic effects at the other. Examples- pentazocine, nalbuphine, meptazinol.

Drugs that do not display antagonistic effects but have diminished effects at opioid receptors: Example- buprenorphine.

MEPTAZINOLMeptazinol is a synthetic analgesic with

mixed agonist-antagonist activity at opioid receptors.

It also has an action via central cholinergic pathways that may contribute to analgesia.

It produces less respiratory depression because of its selectivity for MOP-1 receptors.

Its main disadvantage is a high incidence of nausea & vomiting, that can be reduced by administration of antimuscarinic drugs.

It is one-tenth as potent as morphine. It has rapid onset of action that lasts for 2-4

hours.

BUPRENORPHINEBuprenorphine is 30 times more potent

than morphine. It is highly lipid soluble, & is well absorbed

sublingually. It has low oral bioavailability. Although its terminal half-life is 3-4 hours,

it has a much longer duration of action (up to 8 hours).

In general, buprenorphine & morphine produce similar effects and side effects.

As buprenorphine has extremely high affinity for MOP receptors, its effects are not completely reversed by naloxone (see opioid antagonists).

Respiratory depression may need to be treated with doxapram.

Nausea & vomiting are severe & prolonged.

PENTAZOCINEPentazocine has 25% of the

analgesic potency of morphine. It is not very effective in relieving

severe pain, & this may be partly because of absence of euphoriant effect.

It produces an increase in heart rate & BP.

Nausea, vomiting, bizarre dreams & hallucination are more common than morphine.

MCQMCQ

Which of the following possess(es) some antagonist activity at opioid receptors? A. naloxoneB. pentazocineC. butorphanolD. nalorphineE. Nalbuphine

OPIOID ANTAGONISTSOPIOID ANTAGONISTSNaloxone & its longer acting derivative

naltrexone occupy opioid receptors, but they have essentially no intrinsic activity at these receptors.

Moderate doses administered in absence of an opioid produce no effect; large doses, however, may have effects in which antagonism of endorphins may play a role.

NALOXONENaloxone is a pure opioid agonist & will

reverse opioid effects at MOP, KOP and DOP receptors, although its affinity is highest at MOP receptors.

It is the drug of choice for the treatment of opioid induced respiratory depression.

The usual dose is 200-400micrograms IV, titrated to effect.

Smaller doses (0.5-1.0 microgram/kg) may be titrated to reverse undesirable effects of opioids for example itching associated with the intrathecal or epidural administration of opioids, without significantly affecting the level of analgesia.

NALOXONEThe duration of effective antagonism is

limited to around 30 minutes & therefore longer acting agonists will outlast this effect and further bolus doses or an infusion (5-10 microgram/kg/hr) will be required to maintain reversal.

Caution must be used in opioid addicts as giving naloxone may cause an acute withdrawal state with hypertension, pulmonary oedema & cardiac arrhythmias.

Antanalgesic effects may be observed in opioid naïve subjects who are given naloxone.

NALTREXONENaltrexone has similar

mechanism of action, but has few pharmacokinetic advantages compared to naloxone.

It has longer half-life & is effective orally for up to 24 hours.

It has been used to treat opioid addiction & compulsive eating with morbid obesity.

THANK YOU